Across TCGA pan-cancer cohorts, PRAMEF32P RNA is linked to patient survival in 2 of 34 cancer types, making it the most broadly survival-associated PRAMEF32P data layer.

The strongest signal is observed in thyroid carcinoma (THCA), where higher PRAMEF32P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PRAMEF32P expression acts as an unfavorable survival marker.

THCA and ESCA are the cancer types where PRAMEF32P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	OS	Tertile	All	0.375	0.948	.015	12	view →
ESCA	DFS	Tertile	All	0.146	0.533	.046	9	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: PRAMEF32P tumor-vs-normal RNA expression · all PRAMEF32P data types